21925 W. FIELD PARKWAY, DEER PARK, IL
Reports Second Quarter 2026 Financial Results
Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
Other Events, Press Release
Shareholder votes
Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
Reports First Quarter 2026 Financial Results
Relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
Announces Initiation of Clinical Study for Product Candidate ET-700
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload